Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes?

Diabetologia. 2020 Aug;63(8):1665-1666. doi: 10.1007/s00125-020-05175-8. Epub 2020 May 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies / immunology
  • Autoantibodies / metabolism*
  • Child, Preschool
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / immunology*
  • Diabetes Mellitus, Type 1 / metabolism*
  • Glutamate Decarboxylase / metabolism*
  • Humans
  • Insulin / metabolism
  • Insulin / therapeutic use
  • Nerve Tissue Proteins / metabolism*
  • Receptor-Like Protein Tyrosine Phosphatases, Class 8 / metabolism
  • Tetraspanins / metabolism*
  • Zinc Transporter 8 / metabolism

Substances

  • Autoantibodies
  • Insulin
  • Nerve Tissue Proteins
  • SLC30A8 protein, human
  • TSPAN7 protein, human
  • Tetraspanins
  • Zinc Transporter 8
  • PTPRN protein, human
  • Receptor-Like Protein Tyrosine Phosphatases, Class 8
  • Glutamate Decarboxylase
  • glutamate decarboxylase 2